Adaptive Biotechnologies

Adaptive Biotechnologies CEO Chad Robins has sold approximately $14.88 million worth of company common stock. The sales occurred on August 17 and 18, 2026, at prices ranging between $24.48 and $25.57. This move follows the exercise of stock options, with Mr. Robins acquiring a total of 600,000 shares for approximately $3.93 million. Following these transactions, Mr. Robins directly holds 2,180,518 shares of Adaptive Biotechnologies common stock. The company's stock has gained 107% over the past year, with a 52-week high of $26.16.

Adaptive Biotechnologies reported its second-quarter results, revealing a mixed performance. The company posted an adjusted loss of $0.25 per share, missing the analyst consensus estimate. However, revenue reached $71.6 million, surpassing the analyst estimate and marking a 22% increase from the same quarter last year. Analysts have responded positively to the company's strong revenue growth, with BTIG and Guggenheim raising their price targets for the company. These developments indicate a positive outlook from analysts despite the earnings miss.